Actively Recruiting
Development of an Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment Based on Multimodal Data Fusion Using Deep Learning Technology
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2022-06-21
3000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers aim to create a comprehensive medical database to improve the prediction of cancer risk, screening accuracy, and treatment outcomes. The study focuses on common tumors including lung cancer and pulmonary nodules, stomach cancer, and colorectal cancer. This research combines clinical diagnosis, treatment information, imaging, pathology, and multi-omics data to develop advanced artificial intelligence (AI) technologies for better diagnosis and personalized treatment predictions. The study gathers multiple types of data such as electronic medical records, pathological images, medical imaging like CT and MRI, and various molecular data including genome and proteome information. Using AI, researchers plan to analyze these diverse data sources through deep learning and bioinformatics methods. This approach will address challenges like unbalanced data and small sample sizes to create accurate diagnostic and treatment response models. Participants include those suspected of having lung, stomach, or colorectal cancers, as well as healthy individuals without these diagnoses. The study involves collecting detailed clinical and imaging data along with multi-omics information. Researchers will evaluate outcomes such as diagnosis accuracy for benign or malignant lesions and treatment responses over the study period from 2022 to 2026. Follow-up and detailed record-keeping will support ongoing assessments of cancer diagnosis and therapy effectiveness.
CONDITIONS
Brief Title
Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants suspected of lung cancer or pulmonary nodules, stomach cancer or lesions, or colorectal cancer or lesions
- Participants who have signed informed consent
- Participants with detailed electronic medical records, imaging, pathology, multi-omics data, and other important clinical information
- Healthy participants without clinical diagnosis of lung, stomach, or colorectal cancer or lesions
You will not qualify if you...
- Participants missing primary clinical or pathological data
- Participants lost to follow-up
- Participants with medical images of too poor quality to accurately segment or mark regions of interest
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2022 to 2026
Participants undergo collection of multi-modal clinical data including electronic medical records, medical imaging, pathology, and multi-omics data for assessment of tumor risk and diagnosis.
Initial and periodic data collection visits as needed
Duration - Up to 4 years
Participants are monitored over time to evaluate clinical diagnosis outcomes and treatment responses for lung, stomach, and colorectal cancers.
Regular follow-up visits depending on clinical care
Trial Site Locations
Total: 1 location
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
Y
Yang Jin
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here